版本:
中国

BRIEF-Ultragenyx reports positive interim data from phase 2 studies of KRN23 in X-linked hypophosphatemia

Sept 19 Ultragenyx:

* Reports positive interim data from pediatric and adult phase 2 studies of KRN23 in X-linked hypophosphatemia

* Pediatric study demonstrates substantial reduction in bone disease and improvement in growth

* Adult study demonstrates increase in serum phosphorus and provides evidence of clinical improvement

* Adverse events were consistent with what has been previously observed for KRN23 for treatment of XLH Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐